Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 --0%
Revenue Growth %: +70.6%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +70.6%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
- Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
